Two from Canada and one from China
Suven Life Sciences announced that the grant of two (2) product patents from Canada (2773409, 2785957) and one (1) product patent from China (CN102741239) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2030.The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of twenty (20) granted patents from Canada and eighteen (18) granted patents from China. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Powered by Capital Market - Live News
